Table of Contents
Peginterferon ?2a/Ribavirin FDA Antiviral Drugs Advisory Committee
Disclosure
What Information is Still Pending for the US Treating Community?
What Data Does the Treating Community Have Access to?
Impact of Patient Withdrawals: Absolute number of US patients
Clinical Questions: Absolute number of patients
Treatment Response by Geographic Location: Peginterferon alfa-2b/RBV*
Prevalence of HCV Infection, United States, 1988-1994
Prevalence (%) of Overweight/Obesity Among Males in US, 1999-2000*
If the numbers are available, how should they be analyzed?
Roche Statement on Clinical Trial Analysis
Conclusions (1)
Conclusions (2)
|
Author: Brian Murphy
|